Rotavirus Group and Enteric Virus Group

• 
  Group Leader
  Professor Julie Bines

  Melbourne Childrens Campus

  View researcher's webpage

  +613 9345 4107

Research Overview

Under the campus partnership, our research is embedded in MCRI.  Full research profile may be found at https://www.mcri.edu.au/research/themes/infection-and-immunity/rotavirus or https://www.mcri.edu.au/users/professor-julie-bines.

RV3 Rotavirus Vaccine Program builds on 40 years of internationally recognized contribution to the understanding of rotavirus infection and the development of rotavirus vaccines, led by the group that discovered rotavirus in 1973. The goal of the Program is to develop an effective, low cost, human neonatal rotavirus vaccine aimed at prevention of rotavirus disease from birth. The RV3 Rotavirus Program has led clinical trials for safety, immunogenicty and efficacy in Melbourne, New Zealand and Indonesia.

The Rotavirus Group has also contributed to the understanding of the safety of rotavirus vaccines, in particular Intussusception. The Group were responsible for leading the development of the Brighton Collaboration clinical case definition for intussusception and the validation of the use of this tools for large scale clinical trials of rotavirus vaccines and post-licensure surveillance actvities.

The Enteric Virus Group hosts the Australian Rotavirus Surveillance Network and the WHO Asia-Pacific Regional Reference Laboratory. It is one of only 2  WHO Collaborating Centres for Child Health focusing on rotavirus research. The Group works on a range of projects related to viral pathogens that cause diarrheal disease in humans and animals.

Collaborators

• Universitas Gadjah Madah, Indonesia
• University of Otago New Zealand
• Monash University
• PATH, USA

Funding

• Bill and Melinda Gates Foundation
• National Health and Medical Research Council

Research Publications

• BINES JE, DANCHIN MD, JACKSON P, HANDLEY A, WATTS E,CROWLEY D, LEE K, WEST A, CHEN MY, BARNES GL, JUSTICE F, BUTTERY J, TAYLOR B, KIRKWOOD C.
  Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered in a birth dose or an infnat dose schedule: A randomised, double blind, placebo controlled trial.  Lancet Infectious Diseases 2015; 15 (12):1361-1498.
• DANCHIN M, KIRKWOOD CD, LEE KJ, BISHOP RF, WATTS E, JUSTICE FA, CLIFFORD V, COWLEY D, BUTTERY JP, BINES JE
  Phase I trial of RV3-BB rotavirus vaccine: A human neonatal rotavirus vaccine. Vaccine 2013; 31(23): 2610-16
• DANCHIN M, BINES JE
  Defeating Rotavirus? The Global Recommendation for Rotavirus Vaccination.
  New England Journal of Medicine 2009; 361(20):1919-21
• YEN C, HEALY K, TATE JE, PARASHAR UD, BINES JE, NEUZIL K, SANTOSHAM M, STEELE AD.
  Rotavirus Vaccination and intussusception - science, surveillance, and safety: a review of evidence and recommendations for future research priorities. Human Vaccines and Immunotherapeutics (in press) (PMID:27322835)
• CARLIN JB, MACARTNEY KK, LEE KJ, QUINN HE, BUTTERY J, BINES J, MCINTYRE PB
  Intussusception Risk and Disease Prevention Associated with Rotavirus Vaccines in Australia’s National Immunization Program. Clinical Infectious Diseases 2013; 57(10): 1427-34.